SCHEMBL3830028

SCHEMBL3830028

COc1ccc(C)c(-c2cc3ccc(C)cc3cn2)c1

nearest known ligand 0.55

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.55
RAB9A P51151 7/20 0.55
CASP3 P42574 2/20 0.55
SENP7 Q9BQF6 2/20 0.55
ABL1 P00519 2/20 0.45
CYP11B1 P15538 3/20 0.43
CYP11B2 P19099 3/20 0.43
DHODH Q02127 1/20 0.42
EGFR P00533 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2A6 P11509 1/20 0.38
IDO1 P14902 1/20 0.38
TDO2 P48775 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3828449 0.88 NPC1 (0.55) NPC1RAB9ACASP3SENP7CYP11B1
SCHEMBL14102704 0.81 NPC1 (0.72) NPC1RAB9ACASP3SENP7CYP11B1
SCHEMBL3824837 0.80 NPC1 (0.79) NPC1RAB9ACASP3SENP7EGFR
SCHEMBL3826324 0.78 L3MBTL1 (0.50) NPC1RAB9ACASP3SENP7CYP1A2
SCHEMBL3824825 0.77 NPC1 (0.77) NPC1RAB9ACASP3SENP7CYP1A2
SCHEMBL3826270 0.77 NPC1 (0.64) NPC1RAB9ACASP3SENP7CYP1A2
SCHEMBL510241 0.76 DHFR (0.43) NPC1RAB9ACASP3SENP7CYP11B1
SCHEMBL3825642 0.76 NPC1 (0.71) NPC1RAB9ACASP3SENP7EGFR
SCHEMBL1723322 0.75 ACHE (0.52) RAB9ACYP11B1CYP11B2CYP1A2CYP2A6
SCHEMBL7750 0.73 CYP2A6 (0.65) RAB9ACYP1A2CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2099765-A2 5, 6, OR 7-SUBSTITUTED-3-(HETERO)ARYLISOQUINOLINAMINE DERIVATIVES AS ANTITUMOR AGENTS Rexahn Pharmaceuticals, Inc. (US) 2009-09-16 EP disclosed
WO-2008063548-A2 5, 6, OR 7-SUBSTITUTED-S- (HETERO)ARYLISOQUINOLINAMINE DERIVATIVES AS ANTITUMOR AGENTS REXAHN PHARMACEUTICALS, INC. (US) 2008-05-29 WO disclosed